Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV3 | Q8NET8 | 2/20 | 0.61 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | VNN1 | O95497 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | KCNA5 | P22460 | 4/20 | 0.36 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL625811 | 0.84 | TRPV3 (0.65) | TRPV3NR1I2OPRM1OPRD1OPRK1 | |
| SCHEMBL14956815 | 0.79 | TRPV3 (0.66) | TRPV3NR1I2OPRM1OPRD1OPRK1 | |
| SCHEMBL625858 | 0.79 | TRPV3 (0.66) | TRPV3NR1I2OPRM1OPRD1OPRK1 | |
| SCHEMBL624448 | 0.79 | TRPV3 (0.66) | TRPV3NR1I2OPRM1OPRD1OPRK1 | |
| SCHEMBL14893473 | 0.79 | TRPV3 (0.56) | TRPV3NR1I2VNN1OPRM1OPRD1 | |
| SCHEMBL625908 | 0.78 | TRPV3 (0.65) | TRPV3NR1I2OPRM1OPRD1OPRK1 | |
| SCHEMBL624783 | 0.78 | TRPV3 (0.65) | TRPV3NR1I2OPRM1OPRD1OPRK1 | |
| SCHEMBL14893666 | 0.78 | TRPV3 (0.58) | TRPV3NR1I2OPRM1OPRD1OPRK1 | |
| SCHEMBL625185 | 0.78 | TRPV3 (0.60) | TRPV3NR1I2OPRM1OPRD1OPRK1 | |
| SCHEMBL625794 | 0.76 | TRPV3 (0.62) | TRPV3NR1I2OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2603490-A1 | NOVEL TRPV3 MODULATORS | AbbVie Inc. (US) | 2013-06-19 | — | — | EP | claimed |
| US-20130150409-A1 | NOVEL TRPV3 MODULATORS | ABBVIE INC. (US) | 2013-06-13 | — | — | US | claimed |
| WO-2012019315-A1 | NOVEL TRPV3 MODULATORS | ABBOTT LABORATORIES (US) | 2012-02-16 | — | — | WO | claimed |
| US-9156788-B2 | TRPV3 modulators | ABBVIE INC. (US) | 2015-10-13 | — | — | US | disclosed |
| EP-2771322-A2 | NOVEL TRPV3 MODULATORS | AbbVie Inc. (US) | 2014-09-03 | — | — | EP | disclosed |
| US-8772499-B2 | TRPV3 modulators | ABBVIE INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-8772500-B2 | TRPV3 modulators | ABBVIE INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20140080803-A1 | NOVEL TRPV3 MODULATORS | ABBVIE INC. (US) | 2014-03-20 | — | — | US | disclosed |
| EP-2603490-A1 | NOVEL TRPV3 MODULATORS | AbbVie Inc. (US) | 2013-06-19 | — | — | EP | disclosed |
| US-20130150409-A1 | NOVEL TRPV3 MODULATORS | ABBVIE INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130131036-A1 | NOVEL TRPV3 MODULATORS | ABBVIE INC. (US) | 2013-05-23 | — | — | US | disclosed |
| WO-2013062966-A2 | NOVEL TRPV3 MODULATORS | ABBVIE INC. (US) | 2013-05-02 | — | — | WO | disclosed |
| WO-2013062964-A2 | NOVEL TRPV3 MODULATORS | ABBVIE INC. (US) | 2013-05-02 | — | — | WO | disclosed |
| WO-2012019315-A1 | NOVEL TRPV3 MODULATORS | ABBOTT LABORATORIES (US) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131036-A1 | NOVEL TRPV3 MODULATORS | TRPV3, TRPV4, TRPV5 | TRPV3 1/4885NR1I2 210/4885VNN1 4210/4885 |
| US-20130150409-A1 | NOVEL TRPV3 MODULATORS | TRPV3, TRPV4, TRPV5 | TRPV3 1/4885NR1I2 219/4885VNN1 4154/4885 |
| US-20140080803-A1 | NOVEL TRPV3 MODULATORS | TRPV3, TRPV4, TRPV5 | TRPV3 1/4885NR1I2 221/4885VNN1 4226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.